Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.

[1]  J. Armitage,et al.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Baruchel,et al.  Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Tres,et al.  Increasing dose intensity of cisplatin‐etoposide in advanced nonsmall cell lung carcinoma , 1999, Cancer.

[4]  A. Ravaud,et al.  Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Hidalgo,et al.  A multicenter randomized phase II trial of granulocyte‐colony stimulating factor‐supported, platinum‐based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma , 1998, Cancer.

[6]  W. Scheithauer,et al.  Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. , 1998, European journal of cancer.

[7]  L. Collette,et al.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Verweij,et al.  Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Milleron,et al.  Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Erdkamp,et al.  Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Jones,et al.  Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Nemunaitis,et al.  Randomized placebo‐controlled trial of granulocyte‐macrophage colony‐stimulating‐factor support for dose‐intensive cyclophosphamide, etoposide, and cisplatin , 1996, American journal of hematology.

[13]  M. Pfreundschuh,et al.  Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease , 1995 .

[14]  P. Woll,et al.  Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Kantoff,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Fisher,et al.  Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Wickerham,et al.  The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with met , 1994, American journal of clinical oncology.

[18]  D. Venzon,et al.  A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  B. Bolwell.  Autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. , 1994, Seminars in oncology.

[20]  C. Langer,et al.  Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Schmitz,et al.  Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Queirolo,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. , 1994, British Journal of Cancer.

[23]  R. Souhami,et al.  Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Perkins,et al.  High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion. , 1994, Seminars in oncology.

[26]  C. Osborne,et al.  Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. , 1994, Annals of Oncology.

[27]  G. Rosner,et al.  Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. , 1993, Journal of the National Cancer Institute.

[28]  Dorr Rt.  Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor , 1993 .

[29]  R. Dorr.  Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. , 1993, Clinical therapeutics.

[30]  J. Radford,et al.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.

[31]  Lieschke Gj,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). , 1992, The New England journal of medicine.

[32]  M. Trněný,et al.  [Hematopoietic growth factors. Biology and clinical applications]. , 1992, Casopis lekaru ceskych.

[33]  G. Demetri,et al.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. , 1992, Blood.

[34]  N. Nissen,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Jaffe,et al.  Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Kris,et al.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. , 1994, The New England journal of medicine.

[37]  J. Wagstaff,et al.  Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. , 1991, Journal of the National Cancer Institute.

[38]  D. Betcher,et al.  Granulocyte macrophage colony-stimulating factor , 1991, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[39]  J. Radford,et al.  Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. , 1990, British Journal of Cancer.

[40]  D. Scadden,et al.  Hematopoietic growth factors. Biology and clinical applications. , 1989, The New England journal of medicine.

[41]  C. Stidley,et al.  Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[43]  H. Broxmeyer,et al.  Preclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins , 1989, Immunologic research.

[44]  J. Armitage,et al.  Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Bast,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.

[46]  Hryniuk Wm.  The importance of dose intensity in the outcome of chemotherapy. , 1988 .

[47]  W. Hryniuk.  The importance of dose intensity in the outcome of chemotherapy. , 1988, Important advances in oncology.

[48]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[49]  V. Devita.  Dose-response is alive and well. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  N. Mulder,et al.  High-dose teniposide for refractory malignancies: a phase I study. , 1986, Cancer treatment reports.

[51]  Clark,et al.  Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. , 1986, Blood.

[52]  D. Metcalf.  Granulocyte-macrophage colony-stimulating factors , 1985, Science.

[53]  E. de Vries,et al.  High-dose etoposide for refractory malignancies: a phase I study. , 1984, Cancer treatment reports.

[54]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.